Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) EBT (2020 - 2025)

Historic EBT for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$4.7 million.

  • Gain Therapeutics' EBT fell 581.91% to -$4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.6 million, marking a year-over-year increase of 462.41%. This contributed to the annual value of -$22.4 million for FY2024, which is 39.49% up from last year.
  • Per Gain Therapeutics' latest filing, its EBT stood at -$4.7 million for Q3 2025, which was down 581.91% from -$5.7 million recorded in Q2 2025.
  • In the past 5 years, Gain Therapeutics' EBT registered a high of -$2.4 million during Q1 2021, and its lowest value of -$8.1 million during Q2 2024.
  • Moreover, its 5-year median value for EBT was -$4.7 million (2021), whereas its average is -$4.8 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 55938.68% in 2021, then soared by 3038.6% in 2025.
  • Over the past 5 years, Gain Therapeutics' EBT (Quarter) stood at -$3.2 million in 2021, then tumbled by 42.38% to -$4.6 million in 2022, then dropped by 8.76% to -$5.0 million in 2023, then dropped by 15.59% to -$5.8 million in 2024, then grew by 18.05% to -$4.7 million in 2025.
  • Its EBT stands at -$4.7 million for Q3 2025, versus -$5.7 million for Q2 2025 and -$4.4 million for Q1 2025.